Purpose of review Allogeneic hematopoietic stem cell transplantation (HSCT) is still partially ineffective in curing high-risk hematological malignancies, with estimates of relapse rates ranging from 40 to 50%. The purpose of this review is to discuss the emerging therapeutic options for patients with relapsed disease following HSCT based on adoptive immunotherapy using donor-derived T cells genetically engineered to express CD19- specific chimeric antigen receptors (CARs). Recent findings Adoptive cell therapy (ACT) with CAR-modified T cells represents an attractive therapeutic option for further enhancing the graft-versus-leukemia effect. However, CAR-modified T cells are often obtained using apheresis products collected from the patient's own blood, a procedure that has hindered the application of CAR-based therapies into the clinic. Alternative approaches rely on CAR T cells derived from donors rather than the patient's own blood. Therefore, it appears that overcoming the practical limitation of allogeneic T cell-induced graft versus-host-disease is a key to providing access to CAR immunotherapy to all eligible patients. Summary Donor-derived CD19-CAR T cells may advance the field of CAR immunotherapy by controlling relapse in leukemic patients and improving the range of applications of ACT protocols.

Magnani, C., Biondi, A., & Biagi, E. (2015). Donor-derived CD19-targeted T cells in allogeneic transplants. CURRENT OPINION IN HEMATOLOGY, 22(6), 497-502 [10.1097/MOH.0000000000000178].

Donor-derived CD19-targeted T cells in allogeneic transplants

MAGNANI, CHIARA FRANCESCA
Primo
;
BIONDI, ANDREA
Secondo
;
BIAGI, ETTORE
Ultimo
2015

Abstract

Purpose of review Allogeneic hematopoietic stem cell transplantation (HSCT) is still partially ineffective in curing high-risk hematological malignancies, with estimates of relapse rates ranging from 40 to 50%. The purpose of this review is to discuss the emerging therapeutic options for patients with relapsed disease following HSCT based on adoptive immunotherapy using donor-derived T cells genetically engineered to express CD19- specific chimeric antigen receptors (CARs). Recent findings Adoptive cell therapy (ACT) with CAR-modified T cells represents an attractive therapeutic option for further enhancing the graft-versus-leukemia effect. However, CAR-modified T cells are often obtained using apheresis products collected from the patient's own blood, a procedure that has hindered the application of CAR-based therapies into the clinic. Alternative approaches rely on CAR T cells derived from donors rather than the patient's own blood. Therefore, it appears that overcoming the practical limitation of allogeneic T cell-induced graft versus-host-disease is a key to providing access to CAR immunotherapy to all eligible patients. Summary Donor-derived CD19-CAR T cells may advance the field of CAR immunotherapy by controlling relapse in leukemic patients and improving the range of applications of ACT protocols.
Articolo in rivista - Review Essay
Scientifica
Chimeric antigen receptor; Donor-derived t cells; Hematopoietic stem cell transplantation; Relapse;
English
Magnani, C., Biondi, A., & Biagi, E. (2015). Donor-derived CD19-targeted T cells in allogeneic transplants. CURRENT OPINION IN HEMATOLOGY, 22(6), 497-502 [10.1097/MOH.0000000000000178].
Magnani, C; Biondi, A; Biagi, E
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/97353
Citazioni
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 12
Social impact